HCQ should be used for COVID-19, said ICMR after WHO alert
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
No major side-effects of antimalarial drug Hydroxychloroquine (HCQ) have been found in studies in India and its use can be continued in preventive treatment for Covid-19 under strict medical supervision, the Indian Council of Medical Research (ICMR) said on 26 May 2020.

• The ICMR’s statement came against the backdrop of the World Health Organization (WHO) temporarily suspending the testing of the drug as a potential treatment for Covid-19 over safety concerns.

“The Covid-19 is an evolving field and we do not know which drug is working and which is not working. Lots of drugs are being repurposed for Covid-19, whether for prophylaxis or for treatment of the disease.

• “During these six weeks, we got some data in India, mainly observational studies and some case-control studies. We found there were no major side effects except for nausea, vomiting, palpitation occasionally.

• "Hence in our advisory, we’ve recommended that it should be continued for prophylaxis as there is no harm. The benefit may be there,” ICMR Director General Balram Bhargava said at a press briefing.

• He said it has been “clearly advised that HCQ should be taken with food, not on empty stomach”.

• “We also emphasized that one ECG should be done during the treatment. We expanded the use of HCQ from healthcare workers to front-line workers also, considering the potential benefits,” he added.

• Investigation from three central government hospitals here indicates that amongst healthcare workers involved in Covid-19 care, those on HCQ prophylaxis were less likely to develop SARS-CoV-2 infection, compared to those who were not on it.

• Besides, an observational prospective study of 334 healthcare workers at AIIMS, out of which 248 took HCQ prophylaxis (median 6 weeks of follow-up) here also showed that those taking it had a lower incidence of SARS-CoV-2 than those not taking it.

Source: https://www.hindustantimes.com/india-news/no-major-side-effects-of-hcq-in-studies-in-india-can-be-used-as-preventive-covid-treatment-icmr/story-EflWWnPlVu0FHhV1OH1xoM.html
Dr. P●●●●●●●●a S N●●k and 21 others like this23 shares
Like
Comment
Share
Dr. S●●●●●m S●●●●y P●●●●●l
Dr. S●●●●●m S●●●●y P●●●●●l General Medicine
Now That is really concrete good news. Only responsible statements given by responsible institutions backed by some better than none data relevant in the context of our country can only be believed and followed.
May 27, 2020Like4